Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

4 Nov 2014 07:00

RNS Number : 0309W
Biome Technologies PLC
04 November 2014
 



04 November 2014

 

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the nine months ended 30 September 2014.

 

Total Group revenues achieved for the third quarter were £0.5m (Q3 2013: £0.6m) taking Group revenues for the nine months to 30 September 2014 to £2.8m, 85% ahead of the same period in 2013 (2013: £1.5m). The Group's cash position as at 30 September 2014 was £2.8m (30 June 2014: £3.1m).

Bioplastics Division

Revenues for the Bioplastics division in Q3 were £0.1m (Q3 2013: £0.4m), down substantially on the previous two quarters. Offtake reduced to the single-serve coffee market in the USA as the main customer responded to technical challenges in the market place and ran down stocks ahead of re-launches. The Board believes that these effects are temporary and that revenue growth will resume in the near future.

Further progress was made in the development of the pipeline of new bioplastic polymers with technical and customer trials continuing in both the food service and paper-board coating sectors. The business launched a new product in September, formulated to improve both speed and performance in 3D printing applications, whilst retaining impeccable environmental credentials. This is the division's first foray into this emerging sector and initial response from end-use customers is encouraging.

Earlier in the year, the division announced the successful completion of a feasibility study undertaken in conjunction with the University of Warwick and supported by Innovate UK (formerly the Technology Strategy Board). This study examined the feasibility of producing a bacterially derived lignin-based alternative to the oil-based chemicals used in the manufacture of bioplastics. The Board is exploring options for further scale-up of this technology and is awaiting the result of a further grant application to Innovate UK. The result of this application is expected in the near future.

 

Stanelco RF Technologies Division

Revenues for the RF division remained firm at £0.4m (Q3 2013: £0.2m). Demand from the optical fibre furnace market in Asia continues to underpin revenues whilst products for a broader portfolio of market applications are progressing well. The unit's order-book into 2015 is robust and recruitment has been recently completed to extend both capacity and capability.

 

Outlook

The Board remains confident of meeting market expectations for the year.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Daniel Stewart & Company plc

Paul Shackleton (Nominated Adviser)

Mark Treharne (Broker)

www.danielstewart.co.uk

Tel: +44 (0) 20 7776 6550

Allenby Capital

Chris Crawford/Kelly Gardiner

www.allenbycapital.com

Tel: +44 (0) 20 3002 2070

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKNDBABDDPDK
Date   Source Headline
18th Apr 202310:49 amRNSCompletion of CLN Fundraising
17th Apr 202311:30 amRNSResult of General Meeting
31st Mar 202311:14 amRNSProposed issue of Convertible Loan Notes
25th Jan 20237:00 amRNSTrading Update
16th Nov 20227:00 amRNSBiome receives £282k grant
10th Nov 202211:05 amRNSSecond Price Monitoring Extn
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSTrading Update
18th Oct 20229:28 amRNSHolding(s) in Company
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
5th Sep 20227:00 amRNSGrant funding from Innovate UK
2nd Aug 20228:59 amRNSTrading Update - Replacement
2nd Aug 20227:00 amRNSTrading Update
20th Apr 202212:01 pmRNSResult of Annual General Meeting
20th Apr 20227:00 amRNSTrading Update
30th Mar 20222:48 pmRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSNotice of AGM and 2021 Annual Report
24th Mar 20227:00 amRNSFinal Results 2021
27th Jan 20227:00 amRNSTrading Update
4th Jan 202210:33 amRNSFurther substantial contract win for RF Division
16th Dec 20218:41 amRNSContract
17th Nov 20217:00 amRNSTrading Update
9th Nov 202111:12 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSUpdate re biodegradable tree shelters
15th Sep 20217:00 amRNSInterim Results
30th Jul 20219:47 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSTrading Update
1st Jul 20219:05 amRNSSecond Price Monitoring Extn
1st Jul 20219:00 amRNSPrice Monitoring Extension
1st Jul 20217:00 amRNSTrading Update
30th Jun 20215:00 pmRNSTotal Voting Rights
7th Jun 202110:50 amRNSHolding(s) in Company
2nd Jun 20217:00 amRNSIssue of Equity and TVR
28th May 20217:00 amRNSAward under 2017 Long Term Incentive Plan
30th Apr 20215:00 pmRNSTotal Voting Rights
27th Apr 20214:25 pmRNSHolding(s) in Company
21st Apr 202110:51 amRNSHolding(s) in Company
21st Apr 202110:19 amRNSResult of Annual General Meeting
21st Apr 20217:00 amRNSTrading Update
9th Apr 20211:40 pmRNSPDMR Shareholding and transaction in own shares
1st Apr 202110:04 amRNSIssue of equity and Transaction in own shares
29th Mar 20217:00 amRNSNotice of AGM and Annual Report
25th Mar 20217:01 amRNSFinal Results 2020
25th Mar 20217:00 amRNSAppointment of New Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.